1. Home
  2. ESPR vs IVA Comparison

ESPR vs IVA Comparison

Compare ESPR & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.09

Market Cap

898.5M

Sector

Health Care

ML Signal

HOLD

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

HOLD

Current Price

$6.52

Market Cap

804.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESPR
IVA
Founded
2008
2011
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
898.5M
804.2M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
ESPR
IVA
Price
$3.09
$6.52
Analyst Decision
Buy
Strong Buy
Analyst Count
6
9
Target Price
$6.67
$16.00
AVG Volume (30 Days)
5.6M
414.1K
Earning Date
03-03-2026
09-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$303,802,000.00
$19,929,536.00
Revenue This Year
$26.11
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.83
N/A
52 Week Low
$0.69
$2.11
52 Week High
$4.18
$7.98

Technical Indicators

Market Signals
Indicator
ESPR
IVA
Relative Strength Index (RSI) 32.93 78.22
Support Level $3.00 $4.48
Resistance Level $4.18 $5.17
Average True Range (ATR) 0.23 0.25
MACD -0.11 0.19
Stochastic Oscillator 4.26 94.28

Price Performance

Historical Comparison
ESPR
IVA

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: